Results 211 to 220 of about 1,144,647 (289)

Immunology of Hypertension: Pathophysiological and Therapeutic Aspects. [PDF]

Int J Mol Sci
Manzano A, Parra H, Ariza D, Marquina M, Duran P, Calvo MJ, Nava M, Ross O, Contreras-Velásquez JC, Rivera-Porras D, Bermúdez V.   +10 more
europepmc   +1 more source

A Microbiota‐ and IL‐15‐Dependent Innate‐Like B Cell Progenitor Expressing E4BP4

Advanced Science, EarlyView.
This work identifies CD3.NKp46.CD19.NK1.1. NK‐B cells enriched in PDK1‐deficient yet present in wild‐type bone marrow. IL‐15 (via CD122) and TLR9‐microbiota signaling maintain their E4BP4 expression. These cells demonstrate innate immunity, preferentially differentiate into B cells, and unveil a novel microbiota‐ and IL‐15‐dependent regulatory pathway ...
Junming He, Xinlei Hou, Xiaomei Feng, Yayun Dong, Mengqi Ren, Surong Deng, Xinru Yang, Donglin Chen, Lingna Zhao, Shasha Chen, Meixiang Yang, Zhongjun Dong   +11 more
wiley   +1 more source

The role of immunoglobulin E in non-atopic disorders. [PDF]

Front Immunol
Thaçi K, Gyorgypal A, Anthony RM, Conroy ME.   +3 more
europepmc   +1 more source

CD27 and ICOS as Targets of PD‐1/PD‐L1 Signaling to Regulate Resident Memory CD8+ T‐Cell‐Mediated Pulmonary Protection and Pathology

Advanced Science, EarlyView.
Here it is revealed that the costimulatory receptors CD27 and ICOS are essential for the long‐term maintenance of PD‐1high CD8+ TRM cells following influenza infection. PD‐L1 blockade enhances the proliferation and activation of these cells through Nur77 activation downstream of the CD27/ICOS signaling axis, thereby boosting host immunity against ...
Yuanyuan Chen, Zhenzhen Wang, Liqiang Song, Qianqian Chen, Hang Zhang, Tao Pan, Jianli Pan, Sheng Zhao, Ting Shang, Hong'en Xu, Xing Lv, Jing Li, Fei Kang, Yongzhan Nie, Feng Zhao, Lei Shi, Zheng Wang   +16 more
wiley   +1 more source

Interleukin 1 family dysregulation in serum and peritoneal fluid of ovarian cancer patients - potential clinical implications. [PDF]

Front Oncol
Stępień S, Smycz-Kubańska M, Morawiec ML, Seweryn KR, Mielczarek-Palacz A.   +4 more
europepmc   +1 more source

Bimetallic Peroxide Nanocomposites‐Driven Redox Dyshomeostasis to Activate Sequential Cuproptosis and Pyroptosis for Amplified Tumor Immunotherapy

Advanced Science, EarlyView.
Hyaluronic acid‐modified bimetallic peroxide nanocomposites (MgO2‐CuO2@HA) are designed for synergistic tumor therapy. The nanocomposites release Mg2+, H2O2, and Cu2+ in tumor cells, induce cuproptosis via Cu+‐mediated protein aggregation, and activate pyroptosis through caspase‐1/gasdermin D pathways for inducing immunogenic cell death, collectively ...
Guanting He, Haixia Zhu, Peipei Kang, Lili Feng, Chenghao Yu, Yanlin Zhu, Bin Liu, Zhengxiao Guo, Piaoping Yang   +8 more
wiley   +1 more source

Peroxiredoxin 1, pyroptosis, and the emerging frontier in colorectal cancer therapy. [PDF]

World J Gastroenterol
Maurya DK.
europepmc   +1 more source

NAD+‐Dependent Enzyme SIRT3 Limits Intestinal Epithelial Cell Functions Through NAD+ Synthesis Pathway in Colorectal Cancer

Advanced Science, EarlyView.
Microbiota‐derived quinolinic acid is used as an alternative source of replenishing the intracellular NAD+ pool induced by SIRT3 deficiency to regulate intestinal epithelial cell and T cell function, which has implications for targeting intestinal epithelial cells as an approach to the treatment of immune‐associated diseases, including colorectal ...
Ruiying Niu, Yingjie Dong, Jianghui Tong, Jingxuan Xia, Longhao Zhao, Zi Geng, Yingxin Lin, Jinghe Zhang, Xinyi Liu, Manqi Fang, Xi Jin, Yujing Bi, Guangwei Liu   +12 more
wiley   +1 more source

Esketamine for postoperative sleep disturbance: clinical evidence, mechanisms, and future directions. [PDF]

Front Psychiatry
Liu Q, Liu Y, Fu Q, Gao B, Liu Y.
europepmc   +1 more source

A Rationally Engineered Spleen‐Tropic One‐Component Lipid‐mRNA Complex (OncoLRC) for Cancer Vaccines

Advanced Science, EarlyView.
OncoLRC, a one‐component lipid‐mRNA complex, enables efficient spleen‐targeted delivery at an exceptionally low lipid‐to‐mRNA mass ratio (1.5:1), robustly activates immune responses, inhibits tumor growth, and synergizes with checkpoint blockade, presenting a next‐generation platform for mRNA vaccines.
Qimeng Yin, Chenchen Zhang, Jiahao Li, Kun Huang, Min Qiu   +4 more
wiley   +1 more source